Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
direct-acting antivirals
hepatitis C virus
platelet-associated immunoglobulin G
thrombocytopenia
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
30
10
2018
revised:
03
04
2019
accepted:
08
04
2019
pubmed:
23
4
2019
medline:
10
10
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) infection has been known to cause various extrahepatic autoimmune disorders. The prevalence of platelet-associated immunoglobulin G (PA-IgG) has been high in patients with HCV infection. Because thrombocytopenia in HCV-related liver diseases is a notable problem, we performed prospective study on the effect of direct-acting antivirals (DAAs) treatment on PA-IgG and platelet count. A total of 215 patients with HCV-related liver disease were enrolled in this study. The patients who discontinued DAAs or did not undergo adequate laboratory examinations and who did not achieve sustained virologic response were excluded and finally a total of 187 patients were investigated. A total of 171 patients (91.4%) were PA-IgG positive (>46 ng/10 Eradication of HCV by DAAs treatment successfully decreased PA-IgG level and increased platelet count.
Sections du résumé
BACKGROUND & AIMS
Hepatitis C virus (HCV) infection has been known to cause various extrahepatic autoimmune disorders. The prevalence of platelet-associated immunoglobulin G (PA-IgG) has been high in patients with HCV infection. Because thrombocytopenia in HCV-related liver diseases is a notable problem, we performed prospective study on the effect of direct-acting antivirals (DAAs) treatment on PA-IgG and platelet count.
METHODS
A total of 215 patients with HCV-related liver disease were enrolled in this study. The patients who discontinued DAAs or did not undergo adequate laboratory examinations and who did not achieve sustained virologic response were excluded and finally a total of 187 patients were investigated.
RESULTS
A total of 171 patients (91.4%) were PA-IgG positive (>46 ng/10
CONCLUSIONS
Eradication of HCV by DAAs treatment successfully decreased PA-IgG level and increased platelet count.
Substances chimiques
Antiviral Agents
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1641-1651Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148.
Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66:1282-1299.
Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345-1360.
Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000-1007.
Maan R, van der Meer AJ, Hansen BE, et al. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol. 2014;61:482-491.
Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37:778-793.
Pradella P, Bonetto S, Turchetto S, et al. Platelet production and destruction in liver cirrhosis. J Hepatol. 2011;54:894-900.
Shah SH, Hayes PC, Allan PL, Nicoll J, Finlayson ND. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol. 1996;91:2580-2583.
Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in patients with chronic hepatitis C virus infection. Mediterr J Hematol Infect Dis. 2017;9:e2017019.
Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46:S2-14.
Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 1996;24:135-140.
Aref S, Sleem T, Menshawy EI, et al. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematology. 2009;14:277-281.
Harada M, Fujisawa Y, Sakisaka S, et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol. 2000;35:272-277.
Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenia purpura. Br J Haematol. 2004;124:91-96.
Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol. 1996;25:972-975.
Sevastianos VA, Deutsch M, Dourakis SP, Manesis EK. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol. 2003;98:706-707.
Yesus YW, Scrivner DL, Mitchell MA, Mitra R. A simplified micro ELISA procedure for the measurement of platelet-associated IgG (IgG). Am J Clin Pathol. 1984;81:81-84.
Howe SE, Lynch DM, Lynch JM. An enzyme-linked immunosorbent assay for the quantification of serum platelet-bindable IgG. Transfusion. 1984;24:348-352.
Tsuda M, Imai S, Suzuki H, et al. Measurement of platelet antibody in various diseases. Rinsho Ketsueki. 1988;29:305-312.
Lynch DM, Lynch JM, Howe SE. A quantitative ELISA procedure for the measurement of membrane-bound platelet-associated IgG (PAIgG). Am J Clin Pathol. 1985;83:331-336.
Vallet-Pichard A, Mallet V, Nalpas B, et al. an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-36.
Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921.
Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97:2040-2045.
Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997;26:561-566.
Martyak LA, Yeganeh M, Saab S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin’s lymphoma. Clin Gastroenterol Hepatol. 2009;7:900-905.
Chrétien P, Chousterman M, Abd Alsamad I, et al. Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun. 2009;32:201-205.
Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352:878.
Takashima T, Enomoto H, Iwata Y, et al. Effects of Helicobacter pylori eradication on the platelet count in hepatitis C virus-infected patients. J Clin Med Res. 2016;8:854-858.
Li L, Han DK, Lu J. Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature. World J Gastroenterol. 2010;16:1414-1417.
Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005;75:417-423.